Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
James J. Harding(Memorial Sloan Kettering Cancer Center), Sebastián Mondaca, Madappa N. Kundranda(Banner MD Anderson Cancer Center), Laëtitia Dahan, Ari David Baron, Marine Jary, Filippo de Braud(University of Milan), Mohamedtaki Abdulaziz Tejani(AdventHealth Orlando), Muhammad Shaalan Beg, Elisabetta Fenocchio(Candiolo Cancer Institute), J. Adeva Alfonso, Hui‐Chuan Sun(Fudan University), Myung Ah Lee(The Catholic University of Korea Seoul St. Mary's Hospital), Lequn Bao(Hubei Cancer Hospital), Roopinder Gillmore, Daneng Li(City of Hope), Jieer Ying(Chinese Academy of Sciences), Laura Layos, Omkar Marathe, Sara Lonardi(Istituto Oncologico Veneto), Milind Javle(The University of Texas MD Anderson Cancer Center), Massimo Aglietta(A. O. Ordine Mauriziano di Torino), Antonio Cubillo Gracián(Hospital Universitario HM Sanchinarro), Do‐Youn Oh(Seoul National University), Jung Hun Kang, Emerson Y. Chen(Oregon Health & Science University), Lisa Boyken(Zymeworks (Canada)), Harpreet Wasan(Peter MacCallum Cancer Centre), Eric X. Chen(Princess Margaret Cancer Centre), Hye Jin Choi(Chosun University), Jean‐Philippe Metges(Centre Hospitalier Régional Universitaire de Brest), Ghassan K. Abou‐Alfa(Memorial Sloan Kettering Cancer Center), Teresa Macarulla(Centro de Investigación Biomédica en Red de Cáncer), John Bridgewater(University College Hospital), Jiafang Ma(BeiGene (China)), Shubham Pant(The University of Texas MD Anderson Cancer Center), Michel Ducreux(Université Paris-Saclay), Dong Uk Kim(Pusan National University Hospital), Olumide Gbolohon, Jin Won Kim(Seoul National University), Jia Fan(Fudan University), Ying Cheng(Jilin Province Tumor Hospital), Yuanyuan Bao(BeiGene (China)), Feng Xie, Paula Carrasco Aguirre, Heung-Moon Chang(Ulsan College), Gentry George King, Yixing Jiang, Tingbo Liang(Zhejiang Cancer Hospital), Phillip M. Garfin(Zymeworks (Canada))
Cited by 243
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k